Pancreatic Cancer Research

ResearcherUniversity of FreiburgActive in the last 2 years

Thomas Baptist Brunner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6780-2820; OpenAlex author ID A5080979202, A5128029689. Sources: OpenAlex.

Their work

Papers
35 (first author 1, last author 17)
Trials
0
Grants
0
Labs led
2
Collaborators
105
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 4 papers · 2014: 4 papers · 2015: 5 papers · 2016: 6 papers · 2017: 3 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 35

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Last author DOI 10.1007/s00066-023-02085-7↗
  4. Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents. Co-author DOI 10.3390/jpm12030478↗
  5. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro. Last author DOI 10.1007/s00066-020-01666-0↗
  6. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Co-author DOI 10.1016/j.ctrv.2021.102208↗
  7. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.07.052↗
  8. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  9. Bratislava Statement: consensus recommendations for improving pancreatic cancer care. Co-author DOI 10.1136/esmoopen-2020-001051↗
  10. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus … Last author DOI 10.1007/s00066-017-1099-8↗
  11. Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after … Co-author DOI 10.1016/j.clon.2017.01.038↗
  12. Pancreatic stellate cells in pancreatic cancer: In focus. Last author DOI 10.1016/j.pan.2017.05.390↗
  13. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stere… Co-author DOI 10.1007/s00066-016-1053-1↗
  14. [The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer]. Co-author DOI 10.1007/s00066-016-1058-9↗
  15. Pancreatic cancer chemoradiotherapy. Co-author DOI 10.1016/j.bpg.2016.08.001↗
  16. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.013↗
  17. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Last author DOI 10.1016/j.radonc.2016.03.021↗
  18. The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. Last author DOI 10.1016/j.radonc.2016.03.024↗
  19. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospe… First author DOI 10.1007/s00066-014-0737-7↗
  20. Radiotherapy for SMAD4-negative musculoskeletal lesions from pancreatic cancer: case report and review. Last author DOI 10.1007/s00066-014-0764-4↗
  21. SBRT in pancreatic cancer: what is the therapeutic window? Co-author DOI 10.1016/j.radonc.2014.10.015↗
  22. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - a systematic review. Last author DOI 10.1016/j.radonc.2014.11.043↗
  23. IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. Last author DOI 10.1080/2162402x.2015.1027473↗
  24. The stromal compartments in pancreatic cancer: are there any therapeutic targets? Last author DOI 10.1016/j.canlet.2013.09.039↗
  25. Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells. Last author DOI 10.1016/j.radonc.2014.03.014↗
  26. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-9-146↗
  27. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Last author DOI 10.18632/oncotarget.2519↗
  28. Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor. Last author DOI 10.1007/s00066-013-0332-3↗
  29. Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm? Co-author DOI 10.1007/s11912-012-0291-3↗
  30. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Last author DOI 10.1016/j.radonc.2013.04.010↗
  31. Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advan… Last author DOI 10.3109/0284186x.2013.813072↗
  32. [Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis]. Co-author DOI 10.1007/s00066-012-0079-2↗
  33. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Last author DOI 10.4161/cbt.21093↗
  34. Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling. Last author DOI 10.1158/0008-5472.can-10-1633↗
  35. Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Co-author DOI 10.1186/1748-717x-6-88↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Emmanouil Fokas · 6 shared papers, 2012–2016 · strength 0.33
  2. Serena Lunardi · 6 shared papers, 2011–2016 · strength 0.33
  3. M. Hawkins · 4 shared papers, 2014–2021 · strength 0.32
  4. Somnath Mukherjee · 4 shared papers, 2014–2021 · strength 0.32
  5. Mike Partridge · 5 shared papers, 2013–2017 · strength 0.31
  6. Ruth J. Muschel · 5 shared papers, 2012–2015 · strength 0.26
  7. Falk Roeder · 2 shared papers, 2021–2023 · strength 0.25
  8. Francesco Sclafani · 3 shared papers, 2016–2021 · strength 0.22
  9. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  10. Michael Frederick Bassetti · 1 shared paper, 2026 · strength 0.22
  11. Nina Niu Sanford · 1 shared paper, 2026 · strength 0.22
  12. Michael David Chuong · 1 shared paper, 2026 · strength 0.22
  13. Marsha Reyngold · 1 shared paper, 2026 · strength 0.22
  14. Jessica M. Frakes · 1 shared paper, 2026 · strength 0.22
  15. Karyn A. Goodman · 1 shared paper, 2026 · strength 0.22
  16. Diego A.S. Toesca · 1 shared paper, 2026 · strength 0.22
  17. Daniel Tandel Chang · 1 shared paper, 2026 · strength 0.22
  18. Krishan R. Jethwa · 1 shared paper, 2026 · strength 0.22
  19. Ethan Bernard Ludmir · 1 shared paper, 2026 · strength 0.22
  20. Susan Tsai · 1 shared paper, 2026 · strength 0.22
  21. Amol Kumar Narang · 1 shared paper, 2026 · strength 0.22
  22. Dandan Zheng · 1 shared paper, 2026 · strength 0.22
  23. Matthias Gückenberger · 2 shared papers, 2016–2023 · strength 0.20
  24. James Matthew Wilson · 3 shared papers, 2014–2017 · strength 0.19
  25. Costantinos Zamboglou · 2 shared papers, 2015–2021 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.